What LEAP Meant for Food Allergy
In 2015, a study changed the entire understanding of peanut allergen exposure. Physicians are still trying to understand how to implement it today.
Related Articles
American Academy of Dermatology
Coverage of the American Academy of Dermatology’s annual meeting. Disclaimer: This content was developed independently and is not endorsed by the American Academy of Dermatology.
2-Year Data Shows Relief with Bimekizumab for HS Symptoms, Draining Tunnels
These data presented at AAD 2025 indicate sustained 2-year disease control in key hidradenitis suppurativa (HS) symptoms with bimekizumab-bkzx treatment.
Pollen Food Allergy Syndrome vs Other Allergies, with Antonella Cianferoni, MD, PhD
At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.
American Academy of Dermatology
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care…
AAD 2025: Lebrikizumab Effective in Atopic Dermatitis for Up to 3 Years
New 3-year data from ADjoin demonstrate the efficacy and safety profile of lebrikizumab in moderate to severe atopic dermatitis.
Glycemic Control Influences Outcomes in Central Cicatricial Alopecia, with Crystal Aguh, MD
Crystal Aguh, MD, discusses a study from AAD 2025 examining HbA1c levels and outcomes in CCCA.
AAD 2025: Rocatinlimab, a T-Cell Rebalancing Therapy, for Atopic Dermatitis
Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.
Ruxolitinib Cream 1.5% Shows Promise for Prurigo Nodularis at AAD 2025
Phase 3 data from ruxolitinib cream 1.5% presented at AAD 2025 demonstrate the potential of the topical agent in prurigo nodularis.
Tapinarof Cream 1% Maintains Clear Skin for 80 Days in Atopic Dermatitis, with David Rosmarin, MD
David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.
GLP-1 RAs Could Improve Outcomes in Central Centrifugal Cicatricial Alopecia
Susan Taylor, MD, discusses a study examining the effect of GLP-1 RA use relative to nonuse in central centrifugal cicatricial alopecia at AAD 2025.